MP50-03 [ ⁶⁸ Ga]Ga-FAPI-46 PET/CT PRIOR TO SURGERY IN SQUAMOUS PENILE CANCER – PRELIMINARY CLINICAL RESULTS

You have accessJournal of UrologyCME1 Apr 2023MP50-03 [68Ga]Ga-FAPI-46 PET/CT PRIOR TO SURGERY IN SQUAMOUS PENILE CANCER – PRELIMINARY CLINICAL RESULTS Lennert Eismann, Johannes Toms, Adrien Holzgreve, Elena Berg, Maximilian Schleifele, Severin Rodler, Franz-Josef Gildehaus, Matthias Brendel, Nathalie Albert, Clemens Cyran, Philipp Kazmierczak, Wolfgang Kunz, Stephan Ledderose, Christian Stief, Peter Bartenstein, Marcus Unterrainer, Boris Schlenker, and Lena Unterrainer Lennert EismannLennert Eismann More articles by this author , Johannes TomsJohannes Toms More articles by this author , Adrien HolzgreveAdrien Holzgreve More articles by this author , Elena BergElena Berg More articles by this author , Maximilian SchleifeleMaximilian Schleifele More articles by this author , Severin RodlerSeverin Rodler More articles by this author , Franz-Josef GildehausFranz-Josef Gildehaus More articles by this author , Matthias BrendelMatthias Brendel More articles by this author , Nathalie AlbertNathalie Albert More articles by this author , Clemens CyranClemens Cyran More articles by this author , Philipp KazmierczakPhilipp Kazmierczak More articles by this author , Wolfgang KunzWolfgang Kunz More articles by this author , Stephan LedderoseStephan Ledderose More articles by this author , Christian StiefChristian Stief More articles by this author , Peter BartensteinPeter Bartenstein More articles by this author , Marcus UnterrainerMarcus Unterrainer More articles by this author , Boris SchlenkerBoris Schlenker More articles by this author , and Lena UnterrainerLena Unterrainer More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003298.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: [68Ga]Ga-FAPI-46 PET/CT is an innovative imaging modality for imaging the tumor-associated fibroblasts. The detection of tumor spread in patients with squamous penile cancer, a rare tumor entity, is crucial for therapy planning. Hence, we assessed the clinical feasibility of [68Ga]Ga-FAPI-46 PET/CT in this rare tumor entity. METHODS: Patients with suspected or recurrent penile cancer underwent [68Ga]Ga-FAPI-46 PET/CT imaging for evaluation of the primary tumor site and locoregional lymph node status prior to partial/total penectomy or inguinal/pelvic lymphadenectomy (LAE). Uptake intensities were assessed at the primary sites and at lymph nodes and then compared to histopathological results in a second step. RESULTS: 11 patients with penile cancer (mean 70.1 years) were included and underwent [68Ga]Ga-FAPI-46 PET/CT prior surgical treatment. 7/11 (63.6%) patients received local surgical therapy (partial/total penectomy), 3/11 (27.3%) patients were planned for inguinal/pelvic LAE and 1/11 patients received combined surgery. In 4/8 patients undergoing penectomy, the primary tumor showed increased FAPI uptake (SUVmax 16.2 (9.1 – 25.8)) while in the other 4 patients, the evaluation of primary tumoral site was hampered due to increased urinary activity. 4/11 patients underwent inguinal/pelvic LAE: 3/4 had at least one histopathologically proven pelvic and/or inguinal LN metastasis; all lymph node metastases showed an increased FAPI uptake (SUVmax 17.9 (16.4 – 23.5)) and an enlarged short-axis diameter (1.8 (1.2 – 2.5) cm). Furthermore, in 2/7 patients receiving penectomy only, [68Ga]Ga-FAPI-46 PET/CT revealed enlarged inguinal/pelvic lymph nodes with an distinctly increased FAPI uptake (SUVmax 16.5 (11.4 – 21.6) that could not be addressed during surgery and were subsequently treated by chemotherapy. CONCLUSIONS: In these first experiences in penile cancer, [68Ga]Ga-FAPI-46 PET shows promising clinical performance. [68Ga]Ga-FAPI-46 PET identified all histologically proven lymph node metastases, which might avoid unnecessary LAE and might lead to a reduced morbidity. Improved imaging protocols (e.g. omission of furosemide and urination prior to the scan) might improve evaluation of local tumor burden. Source of Funding: No funding © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e685 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lennert Eismann More articles by this author Johannes Toms More articles by this author Adrien Holzgreve More articles by this author Elena Berg More articles by this author Maximilian Schleifele More articles by this author Severin Rodler More articles by this author Franz-Josef Gildehaus More articles by this author Matthias Brendel More articles by this author Nathalie Albert More articles by this author Clemens Cyran More articles by this author Philipp Kazmierczak More articles by this author Wolfgang Kunz More articles by this author Stephan Ledderose More articles by this author Christian Stief More articles by this author Peter Bartenstein More articles by this author Marcus Unterrainer More articles by this author Boris Schlenker More articles by this author Lena Unterrainer More articles by this author Expand All Advertisement PDF downloadLoading ...